Graphic version of this page | Change how these pages look
Home←Clinical support←Prescribing guidelines←CVS: Spironolactone - Position Statement on MHRA Drug Safety Update
CVS: Spironolactone - Position Statement on MHRA Drug Safety Update prescribing guideline
Key documents
- Summary
- Clinical support by body system
Cardiovascular
- Conditions and indicators
Heart failure
- Due for review
31 March 2018
- Traffic light
- Link
- Bypass detail page
No
- Bypass detail page and
- Clinical Support Group
Cardiovascular and Lipids
Do you want to add this to your CPD record?
Did you find this page helpful?
© 2024
Website by Sitekit, body system icons designed by Freepik